All In Biotech

Drug Trial Radar · NCT05416307

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

A Multipart, Open-label, Single-arm, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

May 19, 2022

Primary completion

Mar 2028

Study completion Mar 2030

Sponsor

Lead sponsor
Electra Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jun 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hemophagocytic lymphohistiocytosis is a rare, aggressive and life-threatening syndrome of excessive immune activation. Secondary hemophagocytic lymphohistiocytosis (sHLH) is the most common form of this disease and is typically associated with several other clinical conditions (eg, malignancy associated HLH (mHLH), infection, or autoimmune disease). ELA026 is a fully human immunoglobulin G1 (IgG1) signal regulatory protein (SIRP)-directed monoclonal antibody designed to deplete the myeloid and T cells driving the inflammation. The purpose of this study is to assess the safety, efficacy pharmacokinetics and pharmacodynamics of ELA026 in participants with sHLH.

Conditions

  • Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Interventions

  • ELA026Drug

    Multiple doses of ELA026

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participant with Incidence of Treatment-Emergent Adverse Events (TEAEs) [Safety and tolerability]Time frame: Up to Week 12
  2. Part 2 (Cohort A): 56-day Survival Rate in Participants with mHLH and Have Lymphoma as the Cancer TriggerTime frame: 56 days

Locations

42 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine

    Birmingham, Alabama · Recruiting

  • Phoenix Children's Hospital

    Phoenix, Arizona · Completed

  • University of California, Los Angeles

    Los Angeles, California · Completed

  • MedStar Georgetown University Hospital

    Washington D.C., District of Columbia · Recruiting

  • Johns Hopkins All Children's Hospital

    St. Petersburg, Florida · Recruiting

  • Children's Healthcare of Atlanta - Center for Advanced Pediatrics

    Atlanta, Georgia · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • National Institute of Allergy and Infectious Diseases (NIAID)

    Rockville, Maryland · Recruiting

  • Columbia University

    New York, New York · Recruiting

  • Cornell University

    New York, New York · Recruiting

  • Hackensack University Medical Center

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Cleveland Clinic Main Campus

    Cleveland, Ohio · Recruiting

  • Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Texas Children's Hospital

    Houston, Texas · Recruiting

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Fred Hutchinson Cancer Center - Seattle Cancer Care Alliance (SCCA) Location

    Seattle, Washington · Recruiting

  • Medizinische Universität Innsbruck

    Innsbruck, Austria · Withdrawn

  • Medical University of Vienna

    Vienna, Austria · Completed

  • Schwarzwald-Baar Klinikum Villingen-Schwenningen

    Villingen-Schwenningen, Germany · Recruiting

  • Universitätsklinikum Jena

    Jena, Thuringia, Germany · Recruiting

  • Azienda Ospedaliero Universitaria Meyer

    Florence, Italy · Recruiting

  • IRCCS Istituto Giannina Gaslini

    Genova, Italy · Recruiting

  • Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico

    Milan, Italy · Completed

  • Fondazione IRCCS San Gerardo dei Tintori (Ospedale San Gerardo)

    Monza, Italy · Recruiting

  • Azienda Ospedale Università di Padova

    Padova, Italy · Recruiting

  • Bambino Gesu' Roma

    Roma, Italy · Withdrawn

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Materno-Infantile Burlo Garofolo

    Trieste, Italy · Recruiting

  • Radboud Universitair Medisch Centrum

    Nijmegen, Netherlands · Recruiting

  • Erasmus UMC

    Rotterdam, Netherlands · Active not recruiting

  • Wilhelmina Kinderziekenhuis

    Utrecht, Netherlands · Recruiting

  • Amsterdam Universitair Medische Centra - Locatie Academisch Medisch Centrum

    Amsterdam, Noord-Holland - NET, Netherlands · Recruiting

  • Hospital 12 de Octubre, Madrid

    Madrid, Spain · Withdrawn

  • Hospital Ramon y Cajal

    Madrid, Spain · Completed

  • Hospital La Fe Valencia

    Valencia, Spain · Withdrawn

  • Clinica Universidad de Navarra - Madrid

    Madrid, Madrid - SPA, Spain · Recruiting

  • Clinica Universidad de Navarra - Pamplona

    Pamplona, Navarre - SPA, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Sevilla - SPA, Spain · Recruiting

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.